Invega Trinza for schizophrenia wins FDA approval

The Food and Drug Administration has approved the long-acting atypical antipsychotic Invega Trinza (3-month paliperidone palmitate) to treat schizophrenia, Janssen Pharmaceuticals announced May 19. Invega Trinza is the first schizophrenia drug to be injected just four times per year, in 3-month intervals, and was approved under FDA priority review, the company said in a statement. […]

Lees verder